Protein Characterization and Identification Market Share, Size, Trends, Industry Analysis Report, By Application (Drug Discovery & Development, Clinical Diagnosis, Others); By Product & Services; By End-Use; By Region; Segment Forecast, 2022 - 2030
- Published Date:Jan-2022
- Pages: 115
- Format: PDF
- Report ID: PM2219
- Base Year: 2021
- Historical Data: 2018 - 2020
Report Outlook
The global protein characterization and identification market was valued at USD 12.41 billion in 2021 and is expected to grow at a CAGR of 14.0% during the forecast period. The rapid technological advancements are driving the growth in the market are allowing for better research techniques, which is expanding the market.
Know more about this report: request for sample pages
One of the primary drivers driving protein characterization and identification adoption is the substantial growth of the biologics and proteomics industries. Also, various governments worldwide are investing heavily in proteomics research supporting protein characterization and identification industry growth. The biopharmaceutical market's goal of blockbuster pharmaceuticals and recent technological improvements in studying genes will continue to be driven by these primary forces.
Furthermore, the major players focus on various strategies such as launching new products, partnerships, and collaborations, among others, driving the protein characterization and identification industry growth during the forecast period. For instance, in June 2021, Thermo Fisher Scientific has announced the launch of the new mass spectrometer for small molecule analysis. The Orbitrap IQ-X Tribrid mass spectrometer from Thermo Scientific was created with small-molecule structure elucidation of compounds and unknown chemicals in consideration.
Metabolomics and lipidomics research the detection of leachable/extractable contaminants, and forensic toxicology are among the many uses. The MS system uses the trusted Thermo Scientific Tribrid architecture to provide a unique, purpose-built AcquireX methodology for acquiring high-quality data. Thus, the launch of the mass spectrometer for protein identification and characterization is boosting the market growth.
However, sample preparation is an important step in isolating the analyte of interest for protein characterization and identification, as it helps to minimize interferences that could alter the result. Lack of understanding about the best technology to employ and how to prepare samples impacts outcomes and results in various direct and indirect costs for end-users. Besides, the high cost of instruments used for the detection, identification, and characterization could be a major restriction for the global market demand for protein characterization and identification.
Know more about this report: request for sample pages
Industry Dynamics
Growth Drivers
The protein characterization and identification market have observed extensive developments in the last few decades supported by various factors such as the rising research and development expenditure for drug discovery and development in the market. The market for protein characterization and identification has benefited from the increasing emphasis on drug research and development. Protein analysis is a crucial stage in the development of pharmaceutical and biological products for identifying viable candidates. As a result, the acceptance of newer medication therapy has boosted the motivation to discover new and sophisticated drugs.
According to the Congressional Budget Office of the US, In 2019, the pharmaceutical sector spent USD 83 billion on research and development. The number of new medications granted each year has also surged during the last decade. From 2010 through 2019, the Food and Drug Administration (FDA) approved an average of 38 new drugs per year (with a high of 59 in 2018), which is 60% more than the previous decade's average.
In 2018, the biopharmaceutical market as a whole spent an estimated USD 102 billion on research and development. One new procedure takes 10-15 years to create and costs USD 2.6 billion, not considering the expense of several failures. Only 12% of new molecular entities that enter clinical trials are approved by the United States Food and Drug Administration (FDA). Thus, the R&D investment by the major government and private institutions is the factor that is boosting the global protein characterization and identification industry growth.
Report Segmentation
The market is primarily segmented based on product & services, application, end-use, and region.
|
By Product & Services |
By Application |
By End-Use |
By Region |
|
|
|
|
Know more about this report: request for sample pages
Insight by Application
Based on the application market division, the drug discovery & development segment is expected to be the most significant revenue contributor in the global protein characterization and identification industry in 2021 and is expected to retain its dominance in the foreseen period. The market segment is expanding as a result of rising R&D spending and an increase in the number of clinical trials for advanced medicines development.
Geographic Overview
In terms of geography, North America had the highest revenue share in 2021 in the global protein characterization and identification market. The presence of prominent players, the availability of financing for breakthrough technologies from government organizations, and increased R&D spending in proteomics research are the major drivers driving protein characterization and identification industry expansion in the region. In August 2021, Metrohm USA and Canada, both manufacturers of high-precision instruments, have signed a partnership agreement with the Agilent to be a re-seller for varied products & services being offered.
Moreover, Asia Pacific is expected to witness a high CAGR in the global protein characterization and identification market in the forecast period. The rising frequency of chronic diseases, global growth by major protein characterization and identification industry participants, and increased market demand for high-quality analytical equipment for protein analysis can all be related to this rise. According to the first Longitudinal Ageing Study in India (LASI) released by the Union Ministry of Family and Health Welfare in January 2020, two out of every three older adults in India suffer from a chronic condition.
Multi-morbidity affects roughly 23% of the elderly population (aged 60 and over); older women are more likely to suffer multi-morbidity diseases. Cardiovascular diseases (CVD) and hypertension are the leading causes of chronic health problems in people aged 75 and up. In the age group under 45, about 73% is determined to be free of morbid conditions, while this percentage drops to 44% in 75 and over. The prevalence of diagnosed CVD is 19% in the 45-49 age group and 37% in over 75. A similar path is followed by chronic hypertension.
Hypertension affects about 18% of people aged 45 to 49, and it rises to 28 percent in those aged 60 to 64 and 35 % in those aged 70 to 74. Bone and joint problems, as well as diabetes, are common among the elderly. In India, diabetes affects 14 % over the age of 60 on average. As a result, the increased prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular disease (CVD), among others, is driving protein characterization and identification industry growth over the projection period in the region.
Competitive Insight
Some of the major players operating in the global protein characterization and identification market include Agilent Technologies, Analytik Jena, Bio-Rad Laboratories, Bruker Corporation, Cleaver Scientific, Danaher Corporation, Eurofins Scientific, Horiba, Jeol, Merck KGAA, PerkinElmer, Promega Corporation, Qiagen, Sartorius AG, Shimadzu Corporation, Thermo Fisher Scientific, and Waters Corporation.
Protein Characterization and Identification Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2021 |
USD 12.41 billion |
|
Revenue forecast in 2030 |
USD 38.67 billion |
|
CAGR |
14.0% from 2022 - 2030 |
|
Base year |
2021 |
|
Historical data |
2018 - 2020 |
|
Forecast period |
2022 - 2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2022 to 2030 |
|
Segments covered |
By Product & Services, By Application, By End-Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key companies |
Agilent Technologies, Analytik Jena, Bio-Rad Laboratories, Bruker Corporation, Cleaver Scientific, Danaher Corporation, Eurofins Scientific, Horiba, Jeol, Merck KGAA, PerkinElmer, Promega Corporation, Qiagen, Sartorius AG, Shimadzu Corporation, Thermo Fisher Scientific, and Waters Corporation. |
